Item 8.01. Other Events.

On August 25, 2008, Stereotaxis, Inc. (NASDAQ: STXS) ("Stereotaxis" or the "Company") announced that Biosense Webster, Inc., Stereotaxis' partner in the development of ablation catheters used with its Niobe Magnetic Navigation System, was notified that it had received CE Mark approval for the commercial sale of the magnetic irrigated catheter in Europe. The Company currently expects that, as a result of this regulatory approval, clinical use of the magnetic irrigated catheter in Europe will take place in the very near term in the context of its partner's pre launch evaluation. Furthermore, with this approval, the Company expects the magnetic irrigated catheter to be used in Europe for the treatment of complex left sided arrhythmias including atrial fibrillation.